Regeneron Pharmaceuticals Inc (BSP:REGN34)
R$ 89.25 1.25 (1.42%) Market Cap: 590.31 Bil Enterprise Value: 549.72 Bil PE Ratio: 24.59 PB Ratio: 3.63 GF Score: 86/100

Regeneron Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 12, 2020 / 12:20PM GMT
Release Date Price: R$55.85
Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst

Okay, everyone, good morning. Welcome to the virtual Vegas conference at Bank of America. This is our first session this morning. We're really happy to have Regeneron this morning presenting. Speaking on behalf of Regeneron is Marion McCourt, who is Senior Vice President and Head of Commercial. Marion, you there?

Marion E. McCourt
Regeneron Pharmaceuticals, Inc. - SVP of Commercial

I am, Geoff, and hello to everybody. Pleasure to join you today.

Questions & Answers

Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst

Okay. Great. So we'll do a Q&A here with the team, and there is an ability to ask a question online as well, if listeners want to do that.

So Marion, let's talk post the first quarter. So it looked like EYLEA sales held up probably a bit better than people thought in the first quarter. Looking to 2Q, what's your expectation for the persistency rates in the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot